Heart imaging and activity tracking in young cancer survivors treated with anthracyclines
Studies heart MRI and activity trackers in childhood cancer survivors at risk of heart failure.
Plain-language title generated from the registry record
Registry title: Cardiotoxicity Assessment Through Comprehensive Heart Imaging to Predict Heart Failure
Key facts
- Where
- San Diego, United StatesSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 13 and 39 years old?
Source: NCT04262830, who can take part
Where in United States
- Rady Children's HospitalSan Diego, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Hari Narayan
- Trial code
- NCT04262830
- Record updated
- 28 January 2025
- Original description
Anthracycline chemotherapies (e.g. doxorubicin, daunorubicin) are commonly given to treat pediatric cancer, and carry a risk of cardiotoxicity. Over the long term, children who receive these therapies have an increased risk of heart failure and early cardiovascular death. However, current strategies for identifying patients who are at risk prior to the development of significant changes in heart function are limited. This study will focus on imaging markers of cardiac injury and dysfunction with the goal of developing improved diagnostic tests and treatment strategies.Read full original descriptionShow less
CATCH-HF: Cardiotoxicity Assessment Through Comprehensive Heart Imaging to Predict Heart Failure
Anthracycline chemotherapies (e.g. doxorubicin, daunorubicin) are commonly given to treat pediatric cancer, and carry a risk of cardiotoxicity. Over the long term, children who receive these therapies have an increased risk of heart failure and early cardiovascular death. However, current strategies for identifying patients who are at risk prior to the development of significant changes in heart function are limited. This study will focus on imaging markers of cardiac injury and dysfunction with the goal of developing improved diagnostic tests and treatment strategies.
Inclusion: English and Spanish speaking male and female subjects, ages 13-39 years old; Diagnosis of cancer at age <22 years; Previously treated with anthracyline therapy for cancer, with diagnosis at least two years prior.
Exclusion: Patients who have a contraindication to cardiac MRI, including the presence of non-MRI compatible metallic implants; Medical, psychiatric, and/or social disorder that would prevent successful completion of planned study testing or would preclude the subject from undergoing the cardiac MRI without anesthesia; Patients with a history of congenital heart disease (more significant than a history of patent foramen ovale or patent ductus arteriosus); Pregnancy (at the time of enrollment).